Released Nov 5, 2025, before the open
10-Q filed Nov 5, 2025, 36 days after period end · 0001171843-25-007005
Q3 2025 · 10-Q
Revenue$0.00$0.00 — vs Q3 2024no prior Q2 2025 on file
Net Income-$14.26M-$14.26M N/M vs Q3 2024N/M vs Q2 2025
EPS, diluted—
Operating Income-$15,817,000N/M
Operating Cash Flowderived-$10,849,000N/M
Free Cash Flowderived-$10,856,000N/M
What the release said
The release
Same quarter
| Metric | Q3 2025 | Q3 2024 | Q3 2023 | Q3 2022 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | — |
| Net Income | -$14.26M | -$10.48M | -$9.96M | -$11.98M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Compass Therapeutics, Inc. · CIK 1738021 · Engraved from SEC EDGAR